Abstract
Background
Our primary objective was to report the current neuroimaging classification systems of spatial patterns of progression in glioblastoma. In addition, we aimed to report the terminology used to describe ‘progression’ and to assess the compliance with the Response Assessment in Neuro-Oncology (RANO) Criteria.
Methods
We conducted a systematic review to identify all neuroimaging studies of glioblastoma that have employed a categorical classification system of spatial progression patterns. Our review was registered with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) registry.
Results
From the included 157 results, we identified 129 studies that used labels of spatial progression patterns that were not based on radiation volumes (Group 1) and 50 studies that used labels that were based on radiation volumes (Group 2). In Group 1, we found 113 individual labels and the most frequent were: local/localised (58%), distant/distal (51%), diffuse (20%), multifocal (15%) and subependymal/subventricular zone (15%). We identified 13 different labels used to refer to ‘progression’, of which the most frequent were ‘recurrence’ (99%) and ‘progression’ (92%). We identified that 37% (n = 33/90) of the studies published following the release of the RANO classification were adherent compliant with the RANO criteria.
Conclusions
Our review reports significant heterogeneity in the published systems used to classify glioblastoma spatial progression patterns. Standardization of terminology and classification systems used in studying progression would increase the efficiency of our research in our attempts to more successfully treat glioblastoma.
Similar content being viewed by others
References
Ostrom QT, Gittleman H, Xu J et al (2016) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro Oncol 18:v1–v75
Price SJ, Gillard JH (2011) Imaging biomarkers of brain tumour margin and tumour invasion. Br J Radiol 84:S159–S167
Friedmann-Morvinski D (2014) Glioblastoma heterogeneity and cancer cell plasticity. Crit Rev Oncog 19:327–336
Zhang W, Le TD, Liu L et al (2017) Mining heterogeneous causal effects for personalized cancer treatment. Bioinformatics 33:2372–2378
Filippini G, Falcone C, Boiardi A et al (2008) Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol 10:79–87
Hochberg FH, Pruitt A (1980) Assumptions in the radiotherapy of glioblastoma. Neurology 30:907–911
Brandes AA, Tosoni A, Franceschi E et al (2009) Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol 27:1275–1279
De Bonis P, Anile C, Pompucci A et al (2013) The influence of surgery on recurrence pattern of glioblastoma. Clin Neurol Neurosurg 115:37–43
Kim J, Lee I-H, Cho HJ et al (2015) Spatiotemporal evolution of the primary glioblastoma genome. Cancer Cell 28:318–328
Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972
Ellingson BM, Wen PY, Cloughesy TF (2017) Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics 14:307–320
Bähr O, Harter PN, Weise LM et al (2014) Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma. Neurology 83:227–234
Choi SH, Kim JW, Chang JS et al (2017) Impact of including peritumoral edema in radiotherapy target volume on patterns of failure in glioblastoma following temozolomide-based chemoradiotherapy. Sci Rep 7:42148
Lundemann M, Costa JC, Law I et al (2017) Patterns of failure for patients with glioblastoma following O-(2-[(18)F]fluoroethyl)-l-tyrosine PET- and MRI-guided radiotherapy. Radiother Oncol 122:380–386
Fujimura M, Kumabe T, Jokura H et al (2004) Intractable vomiting as an early clinical symptom of cerebrospinal fluid seeding to the fourth ventricle in patients with high-grade astrocytoma. J Neurooncol 66:209–216
Blumenthal DT, Artzi M, Liberman G et al (2017) Classification of high-grade glioma into tumor and nontumor components using support vector machine. Am J Neuroradiol 38:908–914
Cachia D, Elshafeey NA, Kamiya-Matsuoka C et al (2017) Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients. J Neurooncol 135:75–81
Rapp M, Baernreuther J, Turowski B et al (2017) Recurrence pattern analysis of primary glioblastoma. World Neurosurg 103:733–740
Straube C, Elpula G, Gempt J et al (2017) Re-irradiation after gross total resection of recurrent glioblastoma: spatial pattern of recurrence and a review of the literature as a basis for target volume definition. Strahlenther Onkol 193:897–909
Lutterbach J, Guttenberger R, Pagenstecher A (2001) Gliosarcoma: a clinical study. Radiother Oncol 61:57–64
Sneed PK, McDermott MW, Gutin PH (1997) Interstitial brachytherapy procedures for brain tumors. Semin Surg Oncol 13:157–166
Khalifa J, Tensaouti F, Lusque A et al (2017) Subventricular zones: new key targets for glioblastoma treatment. Radiat Oncol 12:67
Kondo N, Barth RF, Miyatake S-I et al (2017) Cerebrospinal fluid dissemination of high-grade gliomas following boron neutron capture therapy occurs more frequently in the small cell subtype of IDH1(R132H) mutation-negative glioblastoma. J Neurooncol 133:107–118
Agarwal A, Kumar S, Narang J et al (2013) Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression. J Neurooncol 112:413–420
Agbi CB, Bernstein M, Laperriere N et al (1992) Patterns of recurrence of malignant astrocytoma following stereotactic interstitial brachytherapy with iodine-125 implants. Int J Radiat Oncol Biol Phys 23:321–326
Aiken AH, Chang SM, Larson D et al (2008) Longitudinal magnetic resonance imaging features of glioblastoma multiforme treated with radiotherapy with or without brachytherapy. Int J Radiat Oncol Biol Phys 72:1340–1346
Albert FK, Forsting M, Sartor K et al (1994) Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34:45–60
Alexander E, Loeffler JS (1998) Radiosurgery for primary malignant brain tumors. Semin Surg Oncol 14:43–52
Anderson MD, Hamza MA, Hess KR, Puduvalli VK (2014) Implications of bevacizumab discontinuation in adults with recurrent glioblastoma. Neuro Oncol 16:823–828
Antoni D, Jastaniah Z, Haoming QC et al (2016) Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse. Cancer Radiother 20:282–291
Aydin H, Sillenberg I, von Lieven H (2001) Patterns of failure following CT-based 3-D irradiation for malignant glioma. Strahlenther Onkol 177:424–431
Balducci M, Apicella G, Manfrida S et al (2010) Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report. Strahlenther Onkol 186:558–564
Bashir R, Hochberg F, Oot R (1988) Regrowth patterns of glioblastoma multiforme related to planning of interstitial brachytherapy radiation fields. Neurosurgery 23:27–30
Becker G, Hofmann E, Woydt M et al (1999) Postoperative neuroimaging of high-grade gliomas: comparison of transcranial sonography, magnetic resonance imaging, and computed tomography. Neurosurgery 44:469–477
Bernstein M, Laperriere N, Glen J et al (1994) Brachytherapy for recurrent malignant astrocytoma. Int J Radiat Oncol Biol Phys 30:1213–1217
Biswas A, Kumar N, Kumar P et al (2011) Primary gliosarcoma-clinical experience from a regional cancer centre in north India. Br J Neurosurg 25:723–729
Bloch O, Safaee M, Sun MZ et al (2013) Disseminated progression of glioblastoma after treatment with bevacizumab. Clin Neurol Neurosurg 115:1795–1801
Bokstein F, Kovner F, Blumenthal DT et al (2008) A common sense approach to radiotherapy planning of glioblastoma multiforme situated in the temporal lobe. Int J Radiat Oncol Biol Phys 72:900–904
Buglione M, Pedretti S, Poliani PL et al (2016) Pattern of relapse of glioblastoma multiforme treated with radical radio-chemotherapy: could a margin reduction be proposed? J Neurooncol 128:303–312
Burger MC, Mildenberger IC, Wagner M et al (2017) Bevacizumab for patients with recurrent gliomas presenting with a gliomatosis cerebri growth pattern. Int J Mol Sci 18:E726
Burger PC, Dubois PJ, Schold SC et al (1983) Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg 58:159–169
Chamberlain MC, Barba D, Kormanik P, Shea WM (1994) Stereotactic radiosurgery for recurrent gliomas. Cancer 74:1342–1347
Chamberlain MC (2011) Radiographic patterns of relapse in glioblastoma. J Neurooncol 101:319–323
Champ CE, Siglin J, Mishra MV et al (2012) Evaluating changes in radiation treatment volumes from post-operative to same-day planning MRI in High-grade gliomas. Radiat Oncol 7:220
Chan DTM, Hsieh SYP, Kam MKM et al (2016) Pattern of recurrence and factors associated with cerebrospinal fluid dissemination of glioblastoma in Chinese patients. Surg Neurol Int 7:92
Chan JL, Lee SW, Fraass BA et al (2002) Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 20:1635–1642
Chang EL, Akyurek S, Avalos T et al (2007) Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. Int J Radiat Oncol Biol Phys 68:144–150
Chen L, Chaichana KL, Kleinberg L et al (2015) Glioblastoma recurrence patterns near neural stem cell regions. Radiother Oncol 116:294–300
Cho KH, Kim J-Y, Lee SH et al (2010) Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas. Int J Radiat Oncol Biol Phys 78:390–397
Choucair AK, Levin VA, Gutin PH et al (1986) Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg 65:654–658
Colen RR, Zinn PO, Hazany S et al (2011) Magnetic resonance imaging appearance and changes on intracavitary Gliadel wafer placement: a pilot study. World J Radiol 3:266–272
Desjardins A, Reardon DA, Coan A et al (2012) Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 118:1302–1312
Dobelbower MC, Burnett Iii OL, Nordal RA et al (2011) Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. J Med Imaging Radiat Oncol 55:77–81
Dörner L, Mustafa A, Rohr A et al (2013) Growth pattern of tumor recurrence following bis-chloroethylnitrosourea (BCNU) wafer implantation in malignant glioma. J Clin Neurosci 20:429–434
Douglas JG, Stelzer KJ, Mankoff DA et al (2006) [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 64:886–891
Eisele G, Wick A, Eisele A-C et al (2014) Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. J Neurooncol 117:141–145
Ekinci G, Akpinar IN, Baltacioğlu F et al (2003) Early-postoperative magnetic resonance imaging in glial tumors: prediction of tumor regrowth and recurrence. Eur J Radiol 45:99–107
Elson A, Paulson E, Bovi J et al (2015) Evaluation of pre-radiotherapy apparent diffusion coefficient (ADC): patterns of recurrence and survival outcomes analysis in patients treated for glioblastoma multiforme. J Neurooncol 123:179–188
Elzinga G, Wong ET (2014) Resolution of cystic enhancement to add-on tumor treating electric fields for recurrent glioblastoma after incomplete response to bevacizumab. Case Rep Neurol 6:109–115
Farina P, Tabouret E, Lehmann P et al (2017) Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan. J Neurooncol 132:433–437
Forsting M, Albert FK, Kunze S et al (1993) Extirpation of glioblastomas: MR and CT follow-up of residual tumor and regrowth patterns. Am J Neuroradiol 14:77–87
Gállego Pérez-Larraya J, Lahutte M, Petrirena G et al (2012) Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. Neuro Oncol 14:667–673
Garden AS, Maor MH, Yung WK et al (1991) Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. Radiother Oncol 20:99–110
Gaspar LE, Fisher BJ, Macdonald DR et al (1992) Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys 24:55–57
Gebhardt BJ, Dobelbower MC, Ennis WH et al (2014) Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide. Radiat Oncol 9:130
Giese A, Kucinski T, Knopp U et al (2004) Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma. J Neurooncol 66:351–360
Gobitti C, Borsatti E, Arcicasa M et al (2011) Treatment of recurrent high-grade gliomas with GliaSite brachytherapy: a prospective mono-institutional Italian experience. Tumori 97:614–619
Gunjur A, Bressel M, Ryan G (2012) The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy. J Med Imaging Radiat Oncol 56:567–573
Halligan JB, Stelzer KJ, Rostomily RC et al (1996) Operation and permanent low activity 125I brachytheraphy for recurrent high-grade astrocytomas. Int J Radiat Oncol Biol Phys 35:541–547
Heros DO, Renkens K, Kasdon DL, Adelman LS (1988) Patterns of recurrence in glioma patients after interstitial irradiation and chemotherapy: report of three cases. Neurosurgery 22:474–478
Hess CF, Schaaf JC, Kortmann RD et al (1994) Malignant glioma: patterns of failure following individually tailored limited volume irradiation. Radiother Oncol 30:146–149
Houston SC, Crocker IR, Brat DJ, Olson JJ (2000) Extraneural metastatic glioblastoma after interstitial brachytherapy. Int J Radiat Oncol Biol Phys 48:831–836
Iuchi T, Hatano K, Kodama T et al (2014) Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 88:793–800
Iuchi T, Hatano K, Narita Y et al (2006) Hypofractionated high-dose irradiation for the treatment of malignant astrocytomas using simultaneous integrated boost technique by IMRT. Int J Radiat Oncol Biol Phys 64:1317–1324
Iwamoto FM, Abrey LE, Beal K et al (2009) Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73:1200–1206
Jastaniyah N, Murtha A, Pervez N et al (2013) Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme. Radiat Oncol 8:38
Jia A, Pannullo SC, Minkowitz S et al (2016) Innovative hypofractionated stereotactic regimen achieves excellent local control with no radiation necrosis: promising results in the management of patients with small recurrent inoperable GBM. Cureus 8:e536
Kim BR, Choi SH, Yun TJ et al (2016) MR Imaging analysis of non-measurable enhancing lesions newly appearing after concomitant chemoradiotherapy in glioblastoma patients for prognosis prediction. PLoS ONE 11:e0166096
Kim BS, Kim SK, Choi SH et al (2015) Prognostic implication of progression pattern after anti-VEGF bevacizumab treatment for recurrent malignant gliomas. J Neurooncol 124:101–110
Kim C-S, Jung S, Jung T-Y et al (2011) Characterization of invading glioma cells using molecular analysis of leading-edge tissue. J Korean Neurosurg Soc 50:157–165
Kimura M, Lee Y, Miller R, Castillo M (2013) Glioblastoma multiforme: relationship to subventricular zone and recurrence. Neuroradiol J 26:542–547
Konishi Y, Muragaki Y, Iseki H et al (2012) Patterns of intracranial glioblastoma recurrence after aggressive surgical resection and adjuvant management: retrospective analysis of 43 cases. Neurol Med Chir 52:577–586
Kyritsis AP, Levin VA, Yung WK, Leeds NE (1993) Imaging patterns of multifocal gliomas. Eur J Radiol 16:163–170
Larson DA, Prados M, Lamborn KR et al (2002) Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma. Int J Radiat Oncol Biol Phys 54:1397–1404
Lee IH, Piert M, Gomez-Hassan D et al (2009) Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys 73:479–485
Lee SW, Fraass BA, Marsh LH et al (1999) Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys 43:79–88
Liang BC, Thornton AF, Sandler HM, Greenberg HS (1991) Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg 75:559–563
Lim DA, Cha S, Mayo MC et al (2007) Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol 9:424–429
Loeffler JS, Alexander E, Hochberg FH et al (1990) Clinical patterns of failure following stereotactic interstitial irradiation for malignant gliomas. Int J Radiat Oncol Biol Phys 19:1455–1462
Majós C, Cos M, Castañer S et al (2016) Preradiotherapy MR imaging: a prospective pilot study of the usefulness of performing an MR examination shortly before radiation therapy in patients with glioblastoma. Am J Neuroradiol 37:2224–2230
Mamo A, Baig A, Azam M et al (2016) Progression pattern and adverse events with bevacizumab in glioblastoma. Curr Oncol 23:e468–e471
Masciopinto JE, Levin AB, Mehta MP, Rhode BS (1995) Stereotactic radiosurgery for glioblastoma: a final report of 31 patients. J Neurosurg 82:530–535
Massey V, Wallner KE (1990) Patterns of second recurrence of malignant astrocytomas. Int J Radiat Oncol Biol Phys 18:395–398
Matsuda M, Ishikawa E, Yamamoto T et al (2017) Efficacy of bevacizumab therapy in recurrent malignant gliomas in relation to the prior recurrence pattern or tumor location. J Clin Neurosci 40:115–119
Matsuda M, Yamamoto T, Kumada H et al (2009) Dose distribution and clinical response of glioblastoma treated with boron neutron capture therapy. Appl Radiat Isot 67:S19–S21
McDonald MW, Shu H-KG, Curran WJ, Crocker IR (2011) Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. Int J Radiat Oncol Biol Phys 79:130–136
Mehta MP, Masciopinto J, Rozental J et al (1994) Stereotactic radiosurgery for glioblastoma multiforme: report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. Int J Radiat Oncol Biol Phys 30:541–549
Melguizo-Gavilanes I, Bruner JM, Guha-Thakurta N et al (2015) Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard? J Neurooncol 123:141–150
Milano MT, Okunieff P, Donatello RS et al (2010) Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. Int J Radiat Oncol Biol Phys 78:1147–1155
Minniti G, Amelio D, Amichetti M et al (2010) Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol 97:377–381
Monjazeb AM, Ayala D, Jensen C et al (2012) A phase I dose escalation study of hypofractionated IMRT field-in-field boost for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 82:743–748
Murakami R, Hirai T, Nakamura H et al (2012) Recurrence patterns of glioblastoma treated with postoperative radiation therapy: relationship between extent of resection and progression-free interval. Jpn J Radiol 30:193–197
Nakagawa K, Aoki Y, Fujimaki T et al (1998) High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 40:1141–1149
Narayana A, Kelly P, Golfinos J et al (2009) Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 110:173–180
Narayana A, Kunnakkat SD, Medabalmi P et al (2012) Change in pattern of relapse after antiangiogenic therapy in high-grade glioma. Int J Radiat Oncol Biol Phys 82:77–82
Narayana A, Golfinos JG, Fischer I et al (2008) Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys 72:383–389
Narayana A, Gruber D, Kunnakkat S et al (2012) A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg 116:341–345
Narayana A, Perretta D, Kunnakkat S et al (2011) Invasion is not an independent prognostic factor in high-grade glioma. J Cancer Res Ther 7:331–335
Nestler U, Lutz K, Pichlmeier U et al (2015) Anatomic features of glioblastoma and their potential impact on survival. Acta Neurochir 157:179–186
Niyazi M, Jansen NL, Rottler M et al (2014) Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients. Radiat Oncol 9:299
Niyazi M, Schnell O, Suchorska B et al (2012) FET-PET assessed recurrence pattern after radio-chemotherapy in newly diagnosed patients with glioblastoma is influenced by MGMT methylation status. Radiother Oncol 104:78–82
Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779–787
Nowosielski M, Wiestler B, Goebel G et al (2014) Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology 82:1684–1692
Ogura K, Mizowaki T, Arakawa Y et al (2013) Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution. Radiat Oncol 8:97
Oh J, Sahgal A, Sanghera P et al (2011) Glioblastoma: patterns of recurrence and efficacy of salvage treatments. Can J Neurol Sci 38:621–625
Oppitz U, Maessen D, Zunterer H et al (1999) 3D-recurrence-patterns of glioblastomas after CT-planned postoperative irradiation. Radiother Oncol 53:53–57
Pan H, Alksne J, Mundt AJ et al (2012) Patterns of imaging failures in glioblastoma patients treated with chemoradiation: a retrospective study. Med Oncol 29:2040–2045
Panet-Raymond V, Souhami L, Roberge D et al (2009) Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis. Int J Radiat Oncol Biol Phys 73:473–478
Park I, Tamai G, Lee MC et al (2007) Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings. Int J Radiat Oncol Biol Phys 69:381–389
Petrecca K, Guiot M-C, Panet-Raymond V, Souhami L (2013) Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma. J Neurooncol 111:19–23
Piroth MD, Galldiks N, Pinkawa M et al (2016) Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume. Radiat Oncol 11:87
Pope WB, Xia Q, Paton VE et al (2011) Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology 76:432–437
Price SJ, Jena R, Burnet NG et al (2007) Predicting patterns of glioma recurrence using diffusion tensor imaging. Eur Radiol 17:1675–1684
Puchner MJA, Giese A, Lohmann F, Cristante L (2004) High-dose tamoxifen treatment increases the incidence of multifocal tumor recurrences in glioblastoma patients. Anticancer Res 24:4195–4203
Raizer JJ, Grimm S, Chamberlain MC et al (2010) A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 116:5297–5305
Rostomily RC, Spence AM, Duong D et al (1994) Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery 35:378–388 (discussion 388)
Schaub C, Greschus S, Seifert M et al (2013) FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival. Oncology 85:191–195
Schupak K, Malkin M, Anderson L et al (1995) The relationship between the technical accuracy of stereotactic interstitial implantation for high grade gliomas and the pattern of tumor recurrence. Int J Radiat Oncol Biol Phys 32:1167–1176
Shapiro LQ, Beal K, Goenka A et al (2013) Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma. Int J Radiat Oncol Biol Phys 85:636–642
Sharma RR, Singh DP, Pathak A et al (2003) Local control of high-grade gliomas with limited volume irradiation versus whole brain irradiation. Neurol India 51:512–517
Sherriff J, Tamangani J, Senthil L et al (2013) Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide. Br J Radiol 86:20120414
Shibahara I, Sonoda Y, Saito R et al (2013) The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence. Neuro Oncol 15:1151–1159
Shields LBE, Kadner R, Vitaz TW, Spalding AC (2013) Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme. Radiat Oncol 8:101
Shimato S, Nishizawa T, Ohshima T et al (2016) Patterns of recurrence after resection of malignant gliomas With BCNU wafer implants: retrospective review in a single institution. World Neurosurg 90:340–347
Showalter TN, Andrel J, Andrews DW et al (2007) Multifocal glioblastoma multiforme: prognostic factors and patterns of progression. Int J Radiat Oncol Biol Phys 69:820–824
Soffietti R, Trevisan E, Bertero L et al (2014) Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). J Neurooncol 116:533–541
Souhami L, Seiferheld W, Brachman D et al (2004) Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93 - 05 protocol. Int J Radiat Oncol Biol Phys 60:853–860
Stall B, Zach L, Ning H et al (2010) Comparison of T2 and FLAIR imaging for target delineation in high grade gliomas. Radiat Oncol 5:5
Stummer W, Beck T, Beyer W et al (2008) Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA: case report. J Neurooncol 87:103–109
Suzuki M, Nakamatsu K, Kanamori S et al (2003) Feasibility study of the simultaneous integrated boost (SIB) method for malignant gliomas using intensity-modulated radiotherapy (IMRT). Jpn J Clin Oncol 33:271–277
Takano S, Mashiko R, Osuka S et al (2010) Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity. Brain Tumor Pathol 27:89–94
Tang W, Wang X, Chen Y et al (2015) CXCL12 and CXCR4 as predictive biomarkers of glioma recurrence pattern after total resection. Pathol Biol 63:190–198
Tejada S, Aldave G, Marigil M et al (2014) Factors associated with a higher rate of distant failure after primary treatment for glioblastoma. J Neurooncol 116:169–175
Torok JA, Wegner RE, Mintz AH et al (2011) Re-irradiation with radiosurgery for recurrent glioblastoma multiforme. Technol Cancer Res Treat 10:253–258
Trifiletti DM, Hill C, Garda A et al (2017) Multilesion glioblastoma multiforme in the modern chemo-radiotherapy era: an analysis of pattern of failure and overall survival. J Radiat Oncol 6:57–63
Tsien CI, Brown D, Normolle D et al (2012) Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma. Clin Cancer Res 18:273–279
Tsuboi K, Yoshii Y, Nakagawa K, Maki Y (1986) Regrowth patterns of supratentorial gliomas: estimation from computed tomographic scans. Neurosurgery 19:946–951
Tuettenberg J, Grobholz R, Seiz M et al (2009) Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy. J Cancer Res Clin Oncol 135:1239–1244
Uehara K, Sasayama T, Miyawaki D et al (2012) Patterns of failure after multimodal treatments for high-grade glioma: effectiveness of MIB-1 labeling index. Radiat Oncol 7:104
Wallner KE, Galicich JH, Krol G et al (1989) Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16:1405–1409
Weber DC, Casanova N, Zilli T et al (2009) Recurrence pattern after [(18)F]fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma: a prospective study. Radiother Oncol 93:586–592
Welsh J, Sanan A, Gabayan AJ et al (2007) GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study. Int J Radiat Oncol Biol Phys 68:159–165
Wick W, Chinot OL, Bendszus M et al (2016) Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. Neuro Oncol 18:1434–1441
Wick W, Stupp R, Beule A-C et al (2008) A novel tool to analyze MRI recurrence patterns in glioblastoma. Neuro Oncol 10:1019–1024
Wick A, Dörner N, Schäfer N et al (2011) Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol 69:586–592. https://doi.org/10.1002/ana.22336
Wismeth C, Dudel C, Pascher C et al (2010) Transcranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed high-grade gliomas: phase I clinical results. J Neurooncol 98:395–405
Yanagihara TK, Grinband J, Rowley J et al (2016) A simple automated method for detecting recurrence in high-grade glioma. Am J Neuroradiol 37:2019–2025
Yoo R-E, Choi SH, Kim TM et al (2015) Independent poor prognostic factors for true progression after radiation therapy and concomitant temozolomide in patients with glioblastoma: subependymal enhancement and low ADC value. Am J Neuroradiol 36:1846–1852
Young RJ, Gupta A, Shah AD et al (2011) Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology 76:1918–1924
Zhou X, Liao X, Zhang B et al (2016) Recurrence patterns in patients with high-grade glioma following temozolomide-based chemoradiotherapy. Mol Clin Oncol 5:289–294
Zuniga RM, Torcuator R, Jain R et al (2009) Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91:329–336
Zuniga RM, Torcuator R, Jain R et al (2010) Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J Neurooncol 99:237–242
Sneed PK, Gutin PH, Larson DA et al (1994) Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys 29:719–727
Adeberg S, König L, Bostel T et al (2014) Glioblastoma recurrence patterns after radiation therapy with regard to the subventricular zone. Int J Radiat Oncol Biol Phys 90:886–893
Kim J-H, Jung T-Y, Hwang EC et al (2017) Disease progression patterns of bevacizumab responders with recurrent malignant gliomas. Oncol Lett 14:3529–3535
Macdonald DR, Cascino TL, Schold SC, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
Brandsma D, Stalpers L, Taal W et al (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453–461
Taal W, Brandsma D, de Bruin HG et al (2008) Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113:405–410
Shapiro WR (1999) Current therapy for brain tumors: back to the future. Arch Neurol 56:429–432
Price SJ, Jena R, Burnet NG et al (2006) Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor imaging: an image-guided biopsy study. Am J Neuroradiol 27:1969–1974
Price MS, Matys DT, Joannides DA et al (2017) OP04. Predicting sites of treatment failure and tumour recurrence in the invasive margin of glioblastomas (PRAM-GBM)—trial. Neuro Oncol 19:i24–i25
Macleod MR, Michie S, Roberts I et al (2014) Biomedical research: increasing value, reducing waste. Lancet 383:101–104
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Piper, R.J., Senthil, K.K., Yan, JL. et al. Neuroimaging classification of progression patterns in glioblastoma: a systematic review. J Neurooncol 139, 77–88 (2018). https://doi.org/10.1007/s11060-018-2843-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-018-2843-3